1.58
+0.64%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About NanoRepro
Its shares trade on XETRA under the ticker NN6.DE. It has been listed since 9 October 2012. In the fiscal year to 31 December 2025, it reported revenue of €4.7m and a net loss of €2.0m. At that date it held total assets of €36.8m and shareholders' equity of €36.2m.
NanoRepro AG engages in the development, manufacture, and distribution of diagnostic tests and food supplements for home and professional use. The company is headquartered in Marburg An Der Lahn, Hessen. The company went IPO on 2012-10-09. The firm is engaged in the research of stem cells, which are used in the medical treatment due to their ability to self-renew and differentiate to a range of specialized cell types. Nanorepro AG gathers samples of patients’ stem cells and stores them for the future use. Its portfolio also comprises OTC rapid diagnostic tests, such as OvuQUICK, an ovulation test for women; GraviQUICK, a pregnancy test; MenoQUICK, a menopause test; VagiQUICK, a vaginal yeast test; GlutenCHECK, a test to detect celiac disease; CholesterinCHECK, a test to measure the level of total cholesterol, HDL and LDL, as well as FertiQUICK, a fertility test for men.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 9 Oct 2012
- Employees
- 13
- Website
- nanorepro.com ↗
Leadership
Pay as last reported
- Dr. Olaf StillerChairman of the Supervisory Board, since 2007
- Ms. Lisa JuengstChief Executive Officer, Member of the Executive Board, since 2020
- Ms. Eva BlankDeputy Chairwomen of the Supervisory Board, since 2023
- Mr. Stefan PiehChief Financial Officer, Member of the Executive Board
- Mr. Andre Schulte-SudhofMember of the Supervisory Board
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Nanorepro AG has several strengths that contribute to its success in the market. Firstly, the company specializes in the development and manufacturing of rapid diagnostic tests, which are in high demand across various industries. This expertise allows Nanorepro AG to deliver accurate and reliable products to its customers.
- Another strength of Nanorepro AG is its strong research and development capabilities. The company continuously invests in innovation, allowing them to stay at the forefront of technological advancements in the diagnostics industry. This helps Nanorepro AG to maintain a competitive edge and offer cutting-edge solutions to its customers.
- Furthermore, Nanorepro AG has established a vast distribution network, enabling it to reach a wide customer base globally. This network allows for efficient product delivery and customer support, enhancing customer satisfaction and loyalty.
Weaknesses
- Despite its strengths, Nanorepro AG also faces certain weaknesses that need to be addressed. One of these weaknesses is the company's heavy reliance on a few key clients. This dependency poses a risk to Nanorepro AG's revenue and growth potential, as the loss or reduction of business from these clients could significantly impact the company's financial performance.
- Additionally, the company's product portfolio may not be as diverse as some of its competitors. This narrow focus could limit Nanorepro AG's market reach and potentially hinder its ability to cater to a broader customer base.
Opportunities
- Nanorepro AG operates in a growing market for rapid diagnostic tests, providing numerous opportunities for expansion. With the increasing demand for quick and accurate diagnostics, the company can capitalize on this trend by introducing new products or enhancing existing ones to target specific market segments.
- Additionally, Nanorepro AG can explore potential partnerships or collaborations with other companies in related industries. By leveraging the synergies of such alliances, the company can access new markets, technologies, and expertise, leading to increased growth and market share.
Threats
- Nanorepro AG faces several threats that could impact its operations and market position. One significant threat is the intense competition within the diagnostic industry. Competitors with larger resources and established market presence may pose challenges to Nanorepro AG's growth and market share.
- Additionally, external factors such as regulatory changes or disruptions in the supply chain could also pose threats to the company's operations. Adapting to evolving regulations and ensuring a robust supply chain management system are crucial for Nanorepro AG to mitigate these risks.
- Lastly, economic downturns and market uncertainties can affect customer spending and demand for diagnostic products, potentially impacting Nanorepro AG's revenue and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.